CH210729A - Process for the preparation of a monoester of the androstane series. - Google Patents

Process for the preparation of a monoester of the androstane series.

Info

Publication number
CH210729A
CH210729A CH210729DA CH210729A CH 210729 A CH210729 A CH 210729A CH 210729D A CH210729D A CH 210729DA CH 210729 A CH210729 A CH 210729A
Authority
CH
Switzerland
Prior art keywords
diol
androstane
reaction
preparation
carried out
Prior art date
Application number
Other languages
German (de)
Inventor
Gesellschaft Fuer Chemis Basel
Original Assignee
Chem Ind Basel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chem Ind Basel filed Critical Chem Ind Basel
Publication of CH210729A publication Critical patent/CH210729A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J1/00Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J75/00Processes for the preparation of steroids in general

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Description

  

  Verfahren zur Herstellung eines     Monoesters    der     Androstanreihe.       Es wurde gefunden, dass man zum     Andro-          stan-3,17-diol-17-propionat    gelangen kann,    wenn man     Androstan-3,17-diol-dipropionat     der Formel  
EMI0001.0006     
    mit     hydrolysierend    wirkenden Mitteln be  handelt.  



  Das so gewonnene     Androstan-3,17-diol-17-          propionat    der Formel  
EMI0001.0010     
    bildet farblose Kristalle.    Das oben genannte     Dipropionat    wird  zweckmässig nur mit der zur Abspaltung einer       Propionylgruppe    ausreichenden Menge des       hydrolisierend    wirkenden Mittels behandelt.  Die Reaktion lässt sich z. B. in     Methyl-          oder    Äthylalkohol, aber auch in höheren Al  koholen; in     Diogan,    Aceton und     dergl.    durch  führen.

   Bei Verwendung von Alkoholen findet  meist eine     Umesterung    statt, so dass beträcht  lich weniger als die berechnete Menge Lauge  verbraucht wird. Man ist deshalb nicht an  die berechnete Menge Lauge gebunden, son  dern kann auch mehr oder weniger verwenden.      Dadurch, sowie durch die Konzentration  der Lauge und die Temperatur lässt sich die  Reaktionszeit günstig     beeinflussen.     



  Die neue Verbindung dient als Zwischen  produkt zur Herstellung therapeutisch ver  wendbarer Stoffe oder kann selbst therapeu  tische Verwendung finden.  



       Beispiel:     4,0 g     Androstan-3,17-diol-dipropioriat,     dessen beiden     Hydroxylgruppen    vermutlich       trans-Konfiguration    zukommt, werden mit  1000     cm3    Methylalkohol, dem man vorher  0,45 g     Kaliumhydroxyd    zugesetzt bat, 40  Stunden bei Zimmertemperatur stehen ge-    lassen.

   Nach dem Neutralisieren der Lösung  wird diese im Vakuum stark eingeengt, das  durch partielle     Verseifung    entstandene rohe       Androstan-3,17-diol-17-propionat    mit Wasser  gefällt, in Äther aufgenommen und dann der  Äther     abgedampft.    Den so erhaltenen rohen  Monoester reinigt man unter Entfernung       schwerlöslicher    Bestandteile durch     Umkristal-          lisieren.    Er bildet farblose Kristalle.



  Process for the preparation of a monoester of the androstane series. It has been found that androstane-3,17-diol-17-propionate can be obtained if androstane-3,17-diol-dipropionate of the formula
EMI0001.0006
    with hydrolyzing agents.



  The androstane-3,17-diol-17-propionate of the formula obtained in this way
EMI0001.0010
    forms colorless crystals. The above-mentioned dipropionate is expediently treated only with the amount of the hydrolyzing agent which is sufficient to split off a propionyl group. The reaction can be z. B. in methyl or ethyl alcohol, but also in higher Al alcohols; in Diogan, acetone and the like. Perform.

   When alcohols are used, transesterification usually takes place, so that considerably less than the calculated amount of lye is used. You are therefore not bound to the calculated amount of lye, but can use more or less. This, as well as the concentration of the lye and the temperature, can favorably influence the reaction time.



  The new compound serves as an intermediate product in the manufacture of therapeutically usable substances or can be used therapeutically itself.



       Example: 4.0 g of androstane-3,17-diol-dipropioriate, whose two hydroxyl groups presumably have a trans configuration, are left to stand for 40 hours at room temperature with 1000 cm3 of methyl alcohol to which 0.45 g of potassium hydroxide has been added beforehand .

   After the solution has been neutralized, it is strongly concentrated in vacuo, the crude androstane-3,17-diol-17-propionate formed by partial saponification is precipitated with water, taken up in ether and then the ether is evaporated off. The crude monoester obtained in this way is purified by recrystallization while removing sparingly soluble constituents. It forms colorless crystals.

 

Claims (1)

PATENTANSPRUCH: Verfahren zur Darstellung von Androstan- 3,17-diol-17-pr-opionat, dadurch gekennzeich net, dass man Arrdrostan-3,17-diol-dipropionat der Formel EMI0002.0017 mit hydrolysierend wirkenden Mitteln be handelt. Das so gewonnene Androstan-3,17-diol-17- propionat der Formel EMI0002.0021 bildet farblose Kristalle. Die neue Verbindung dient als Zwischen produkt zur Herstellung therapeutisch ver wendbarer Stoffe oder kann selbst therapeu tische Verwendung finden. <B>UNTERANSPRÜCHE:</B> 1. Verfahren nach Patentanspruch, dadurch gekennzeichnet, dass man die Reaktion in indifferenten Lösungsmitteln vornimmt. 2. Claim: Process for the preparation of androstane-3,17-diol-17-pr-opionate, characterized in that arrdrostane-3,17-diol-dipropionate of the formula EMI0002.0017 with hydrolyzing agents. The androstane-3,17-diol-17-propionate of the formula obtained in this way EMI0002.0021 forms colorless crystals. The new compound serves as an intermediate product in the manufacture of therapeutically usable substances or can be used therapeutically itself. <B> SUBClaims: </B> 1. Method according to patent claim, characterized in that the reaction is carried out in inert solvents. 2. Verfahren nach Patentanspruch, dadurch gekennzeichnet, dass man die Reaktion in Alkoholen vornimmt. 3. Verfahren nach Patentanspruch und Unter anspruch 2, dadurch gekennzeichnet, dass man die Reaktion in Methylalkohol vor nimmt. 4. Verfahren nach Patentanspruch, dadurch gekennzeichnet, dass nur die zur Abspal tung einer Propionylgruppe ausreichende Menge des hydrolysierend wirkenden Mit tels verwendet wird. Process according to claim, characterized in that the reaction is carried out in alcohols. 3. The method according to claim and sub-claim 2, characterized in that the reaction is carried out in methyl alcohol. 4. The method according to claim, characterized in that only the amount of the hydrolyzing agent is used which is sufficient to split off a propionyl group.
CH210729D 1935-06-18 1935-06-18 Process for the preparation of a monoester of the androstane series. CH210729A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH210729T 1935-06-18
CH207719T 1935-06-18

Publications (1)

Publication Number Publication Date
CH210729A true CH210729A (en) 1940-07-31

Family

ID=25724442

Family Applications (1)

Application Number Title Priority Date Filing Date
CH210729D CH210729A (en) 1935-06-18 1935-06-18 Process for the preparation of a monoester of the androstane series.

Country Status (1)

Country Link
CH (1) CH210729A (en)

Similar Documents

Publication Publication Date Title
CH210729A (en) Process for the preparation of a monoester of the androstane series.
CH210727A (en) Process for the preparation of a monoester of the androstene series.
CH207719A (en) Process for the preparation of a monoester of the androstane series.
CH210725A (en) Process for the preparation of a monoester of the androstene series.
CH210724A (en) Process for the preparation of a monoester of the androstene series.
CH210726A (en) Process for the preparation of a monoester of the androstene series.
CH210728A (en) Process for the preparation of a monoester of the androstene series.
CH222950A (en) Process for the preparation of a monoester of the androstene series.
CH222952A (en) Process for the preparation of a monoester of the androstane series.
CH222946A (en) Process for the preparation of a monoester of the androstene series.
CH210723A (en) Process for the preparation of a monoester of the androstene series.
CH222951A (en) Process for the preparation of a monoester of the androstane series.
CH222947A (en) Process for the preparation of a monoester of the androstene series.
CH222949A (en) Process for the preparation of a monoester of the androstene series.
DE1807585C3 (en) 14,15beta-epoxy cardenolides, processes for their preparation and compositions containing them
DE936592C (en) Process for the production of a blood and urine sugar lowering preparation from trioxyflavone glucoside-containing parts of plants
CH222955A (en) Process for the preparation of a monoester of the androstane series.
CH222954A (en) Process for the preparation of a monoester of the androstane series.
DE1643174C3 (en) Process for the preparation of 16 acyl gitoxin
CH222956A (en) Process for the preparation of a monoester of the androstane series.
DE956047C (en) Process for the production of furano (4 &#39;, 5&#39;: 6, 7) chromones
CH222953A (en) Process for the preparation of a monoester of the androstane series.
DE843415C (en) Process for the preparation of a guaiacol derivative
CH222948A (en) Process for the preparation of a monoester of the androstene series.
DE1804392A1 (en) 9-0-Kalamycin derivatives and process for their preparation